Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 29, 110-115, January 1, 1969]
© 1969 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloch, A.
Right arrow Articles by Nichol, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloch, A.
Right arrow Articles by Nichol, C. A.

Studies on the Biologic Activity and Mode of Action of 7-Deazainosine1

Alexander Bloch, Enrico Mihich, Robert J. Leonard and Charles A. Nichol

Department of Experimental Therapeutics, Roswell Park Memorial Institute, Buffalo, New York 14203

Deazainosine was prepared by deamination of the antibiotic deazaadenosine (tubercidin). Whereas tubercidin inhibited the growth of Streptococcus faecalis, deazainosine was inactive against this organism. In contrast, both nucleoside analogs inhibited the growth of Sarcoma 180 cells in vitro and Ehrlich ascites and leukemia P388 cells in vivo. The lack of activity against S. faecalis is accompanied by the inability of the organism to convert deazainosine to tubercidin derivatives. Since the sensitive mammalian cells do carry out the amination reaction, this metabolic conversion appears to be required for biologic activity. A comparative evaluation of the antitumor activity of the two compounds showed that approximately 0.25–0.5 mg/kg of tubercidin produced the same effect as 4–8 mg/kg of deazainosine. This difference in potency may reflect the rate at which the conversion of deazainosine to tubercidin nucleotides occurs in sensitive cells. The more limited spectrum of tissue toxicity of deazainosine as compared to tubercidin may result from differences in the capacity of the tissues to carry out the metabolic conversion.

1 This study was aided by Grant T-436 from the American Cancer Society and by Grant CA-04130 from the National Cancer Institute, USPHS.

Received 4/29/68. Accepted 9/30/68.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1969 by the American Association for Cancer Research.